Free Trial
NASDAQ:MGTX

MeiraGTx Q2 2024 Earnings Report

MeiraGTx logo
$7.88 +0.26 (+3.41%)
As of 02:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MeiraGTx EPS Results

Actual EPS
-$0.76
Consensus EPS
-$0.31
Beat/Miss
Missed by -$0.45
One Year Ago EPS
N/A

MeiraGTx Revenue Results

Actual Revenue
$0.28 million
Expected Revenue
$16.38 million
Beat/Miss
Missed by -$16.10 million
YoY Revenue Growth
N/A

MeiraGTx Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Monday, August 12, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

MeiraGTx's Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Tuesday, August 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

MeiraGTx Earnings Headlines

The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
MeiraGTx Holdings plc (MGTX) - Yahoo Finance
See More MeiraGTx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MeiraGTx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MeiraGTx and other key companies, straight to your email.

About MeiraGTx

MeiraGTx (NASDAQ:MGTX), a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

View MeiraGTx Profile

More Earnings Resources from MarketBeat